Vemlidy (tenofovir alafenamide) / Gilead - LARVOL DELTA

Atherosclerotic Cardiovascular Risk in Patients with Chronic Hepatitis B: Tenofovir Disoproxil Fumarate Vs. Tenofovir Alafenamide: A Korean Nationwide Study. (PubMed, J Med Virol) - "Older age, male sex, hypertension, current smoking, and aspartate aminotransferase ≥ 40 U/L were risk factors for ASCVD development. Despite concerns about lipid metabolism, TAF did not increase ASCVD risk compared with TDF, offering reassurance for clinicians selecting antiviral therapies for patients with CHB."

Journal • Retrospective data • Atherosclerosis • Cardiovascular • Hepatitis B • Hypertension • Infectious Disease • Inflammation • Metabolic Disorders

Sex and gender differences in weight gain associated with second-generation integrase strand transfer inhibitors: A scoping review. (PubMed, HIV Med) - "Second-generation INSTIs, especially dolutegravir, appear to be associated with greater average and excessive weight gain among cis women, although this effect varies by setting, regimen and clinical context. Further research, especially in diverse populations, is needed to explore underlying mechanisms, determine risk factors and evaluate these trends in newer antiretroviral medications."

Journal • Review • Human Immunodeficiency Virus • Infectious Disease

Clinical evaluation of lipid profile changes in renal transplant recipients on tenofovir alafenamide for HBV reactivation prophylaxis (ESCMID Global 2026) - No abstract available

Clinical • Hepatitis B • Transplantation

Efficacy and Safety of Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate for Preventing Mother-to-Child Transmission of Hepatitis B in Treatment-Naïve mothers: An Observational Study. (PubMed, Virol J) - "Both TAF and TDF are effective in preventing HBV MTCT, with comparable MTCT rates. However, TAF demonstrated superior renal safety, making it a preferable option for preventing HBV MTCT in treatment-naïve mothers."

Journal • Observational data • Hepatitis B • Infectious Disease • Inflammation

A retrospective comparative study of tenofovir alafenamide and tenofovir disoproxil fumarate in chronic hepatitis B patients: Renal and bone safety versus antiviral efficacy. (PubMed, Medicine (Baltimore)) - "In this retrospective cohort, TAF demonstrated significantly better renal and bone safety profiles than TDF after 12 months of treatment, while achieving equivalent antiviral efficacy. For CHB patients at risk of renal or bone impairment, TAF may represent a safer long-term therapeutic option."

Clinical • Journal • Observational data • Retrospective data • Acute Kidney Injury • Hepatitis B • Infectious Disease • Inflammation • Nephrology • Renal Disease

Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection-General and Special Populations. (PubMed, Aliment Pharmacol Ther) - "Current first-line NUCs show comparable renal safety profiles in CHB patients with no or mild kidney dysfunction, with growing evidence that favours TAF. Future prospective studies are needed to validate these findings, and more research should focus on CHB patients with diabetes mellitus who are at risk of CKD."

Journal • Review • Chronic Kidney Disease • Diabetes • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Liver Failure • Metabolic Disorders • Nephrology • Renal Disease • Transplantation

Bictegravir concentrations in breastmilk of healthy, lactating women without HIV. (PubMed, J Antimicrob Chemother) - "Exposure to bictegravir through breastmilk is very low, with a relative infant dose below 1%. Even though metabolizing capacity in newborns is not yet fully developed, it is not expected to cause infant toxicity."

Journal • Human Immunodeficiency Virus • Infectious Disease

ALEH position statement on the management of hepatitis B virus infection 2025. (PubMed, Ann Hepatol) - "Expanded treatment criteria include patients with significant fibrosis, elevated HBV DNA levels, co-infections, and other risk factors, ensuring broader access to antiviral therapy with tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV). Additionally, universal HDV testing in HBV-infected patients is recommended. These guidelines highlight the urgent need for decentralization, simplification, and equity in HBV management to achieve elimination goals in Latin America by 2030."

Clinical guideline • Journal • Fibrosis • Hepatitis B • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Oncology • Solid Tumor

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: Gilead Sciences | Active, not recruiting ➔ Recruiting

Enrollment open • Hepatitis B • Infectious Disease • Inflammation • B2M

A Study on the Efficacy and Pharmacoeconomics of Tenofovir Alafenamide versus Tenofovir Amibufenamide in the Treatment of Chronic Hepatitis B (ChiCTR) - P=N/A | N=138 | Completed | Sponsor: The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University

New trial • Hepatitis B • Infectious Disease • Inflammation

Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg-Negative Patients With Normal Alanine Aminotransferase: A 48-Week Randomised Controlled Trial. (PubMed, J Viral Hepat) - P=N/A | "Accordingly, early antiviral treatment may benefit this patient population. Trial Registration: Clinical trial number: NCT04231565."

Clinical • Journal • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Letter: Concerns Regarding the Paradoxical Renal Outcomes in Patients Switching From Entecavir to Tenofovir Alafenamide in the Study by Ogawa et al. (PubMed, J Gastroenterol Hepatol) - No abstract available

Journal

DD-PrEP:: Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Johns Hopkins University

New P1 trial • Human Immunodeficiency Virus • Infectious Disease

Reply to "Concerns Regarding the Paradoxical Renal Outcomes in Patients Switching From Entecavir to Tenofovir Alafenamide". (PubMed, J Gastroenterol Hepatol) - No abstract available

Journal

Efficacy and tolerability of tenofovir alafenamide fumarate prophylaxis in HBV-infected individuals receiving chemo/immunosuppressive therapy. (PubMed, Hepatol Forum) - "No significant differences were found in the glomerular filtration rate change or hypophosphatemia during TAF prophylaxis, but the serum triglyceride levels were significantly increased (p=0.019). TAF prophylaxis is effective, safe, and tolerable in preventing chemo/immunosuppressive or biological modifier-induced HBV reactivation in HBV-infected or HBV-experienced individuals."

Journal • Hepatitis B • Infectious Disease • Oncology • Renal Disease • Solid Tumor

A Response to: Letter to the Editor Regarding "Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States". (PubMed, Infect Dis Ther) - No abstract available

Journal • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

FAM83A promotes the progression of lung squamous cell carcinoma by inducing the epithelial-mesenchymal transition and inhibiting apoptosis via ERK pathway. (PubMed, Lung Cancer) - "FAM83A is crucial in the advancement and spread of LUSC, as it promotes EMT and inhibits apoptosis via the activation of the ERK pathway. These findings highlight its potential as a strategic molecular target for the treatment of LUSC."

IO biomarker • Journal • Non Small Cell Lung Cancer • Oncology • Squamous Cell Carcinoma • BCL2 • CASP3 • CCND1 • CDH1 • CDH2 • FAM83A • VIM

Letter to the Editor Regarding "Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States". (PubMed, Infect Dis Ther) - No abstract available

Journal • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

A novel anoikis resistance-associated gene model for prognostic prediction and immune microenvironment characterization in lung squamous cell carcinoma. (PubMed, Discov Oncol) - "This validated ARG-based prognostic model effectively predicts survival outcomes and revealed strong associations between anoikis resistance, immune landscape alterations, and immunotherapy response, offering a framework for risk stratification and precision immunotherapy in LUSC clinical management."

IO biomarker • Journal • Non Small Cell Lung Cancer • Oncology • Squamous Cell Carcinoma • CD8 • ITGA3

Improvement in kidney function in patients with chronic hepatitis B and chronic kidney disease after switching to tenofovir alafenamide fumarate: a systematic review with single arm meta-analysis. (PubMed, J Bras Nefrol) - "The clinical relevance of TAF for HBV patients with CKD aligns with current guideline shifts favoring TAF. Despite limitations such as high heterogeneity, this study supports TAF as a safer management strategy for HBV patients with CKD, demonstrating improved kidney outcomes and reduced nephrotoxicity risks. These findings support its broader use in clinical practice and highlight the need for further research on long-term renal outcomes."

Clinical • Journal • Retrospective data • Review • Chronic Kidney Disease • Hepatitis B • Infectious Disease • Inflammation • Nephrology • Renal Disease

The antiretroviral drug emtricitabine increases kynurenine : tryptophan ratio, aryl hydrocarbon receptor activation, and cellular senescence in female mice. (PubMed, Biochimie) - "FTC, alone or in combination with other ART (tenofovir alafenamide and tenofovir disproxil fumarate), activated AhR and induced senescence of female myoblasts in a manner comparable to KYN. Our studies suggest that the combined presence of HIV viral proteins and exposure to ART induced activation of AhR-mediated signaling in female muscle, as well as widespread changes across the skeletal muscle transcriptome and methylation landscape that may contribute to development of muscle dysfunction. This suggests AhR may represent a novel target for addressing persistent disparities in healthspan for PLWH."

Journal • Preclinical • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • GNAS

Pharmacokinetics of Twice-Daily Tenofovir Alafenamide In Adults with HIV-Associated TB on BIC/FTC/TAF and Rifampicin. (PubMed, Clin Infect Dis) - P2 | "Twice-daily TAF was safe and efficacious and achieved similar exposures of intracellular TFV-DP in PWH taking rifampicin for TB compared to once-daily TAF taken alone. These data support the use of TAF in a fixed-dose combination of BIC/FTC/TAF during rifampicin-containing TB treatment."

Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: Beijing Continent Pharmaceutical Co, Ltd.

New P1 trial • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Changes in Body Mass Index in Children and Adolescents Living With Human Immunodeficiency Virus in Europe and Thailand Starting Dolutegravir. (PubMed, Open Forum Infect Dis) - "In multivariable models, greatest increases in zBMI were in those aged 6-11 years at DTG start (0.34 [95% CI .23-.44]), males of "other" ethnicity (0.39 [95% CI .10-.68]), Black females (0.27 [95% CI .15-.39]), and those on tenofovir alafenamide (TAF) (0.39 [95% CI .17-.61]). CALHIV experienced zBMI increases on DTG with the largest gains in children aged 6-11 years, on TAF, with low baseline zBMI, and some variation by sex and ethnicity. However, zBMI changes over 96 weeks were comparable between those on DTG- and PI-based regimens."

Journal • Human Immunodeficiency Virus • Infectious Disease • Obesity

Association between deletions in the preS1/2 region of the hepatitis B virus genome and persistently abnormal ALT levels in patients with chronic hepatitis B treated with nucleos(t)ide analogs. (PubMed, Arch Virol) - "Out of the 198 patients with CHB who had been treated with NAs, 40 who had been treated with entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide fumarate as the first-line therapy and from whom serum samples had been collected before NA treatment were selected for analysis of the infecting virus. The high-del group also had significantly higher ALT levels than the low-del group after 1 year of NA treatment (35 vs. 26 U/L, P = 0.020). In summary, patients with CHB with frequent preS1/2 deletions showed higher ALT levels after NA treatment and a higher risk of developing HCC."

Journal • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Inflammation • Oncology • Solid Tumor